Health Score

0 Excellent

Metadata coverage

Abstract

ORCID

References

License

Extended metadata coverage

Informational — signals of interoperability and funding across the corpus. Not part of the health score.

Funding

Funder

Award / grant

Affiliation & institutional identifiers

Affiliation

ROR ID

Update policy

Your prioritized action plan

Ordered by how many DOIs each fix touches — start here, not with every error at once.

Attach ORCID iDs across 124 articles

ORCID iDs strengthen author disambiguation and institutional reporting.

Medium impact124 DOIs

Deposit reference lists for 54 records

Deposited references power Crossref's Cited-by links between your articles and the literature.

Low impact54 DOIs

Add abstracts to 19 articles

Abstracts are what surface your work in Google Scholar, Dimensions, and OpenAlex.

Low impact19 DOIs

DOIs for this ISSN

Showing the top 5 of 269 DOIs, ordered by correction priority.

#	Title	Missing	Priority	Citations
1	Trastuzumab-mediated cardiotoxicity: current understanding,… (10.1093/abt/tby003)	ORCID License	92.56	70
2	Ancient species offers contemporary therapeutics: an update… (10.1093/abt/tbaa001)	ORCID License	76.57	33
3	Perspectives on the development of neutralizing antibodies a… (10.1093/abt/tbaa009)	ORCID License	67.12	21
4	Mechanisms contributing to ado-trastuzumab emtansine-induced… (10.1093/abt/tbab005)	ORCID License	60.21	15
5	The global landscape of approved antibody therapies (10.1093/abt/tbac021)	ORCID	51.13	110
6	US FDA-approved therapeutic antibodies with high-concentrati… (10.1093/abt/tbab027)	ORCID	46.58	72
7	A novel IgM intranasal intervention against SARS-CoV-2 (10.1093/abt/tbab019)	Abstract ORCID License	45.15	3
8	Inaugural Editorial: Searching for Magic Bullets (10.1093/abt/tby001)	Abstract ORCID	45.15	7
9	COVID-19 antibody therapeutics tracker: a global online data… (10.1093/abt/tbaa020)	License	44.09	57
10	Biology drives the discovery of bispecific antibodies as inn… (10.1093/abt/tbaa003)	ORCID	42.90	51
11	Current trends and challenges in the downstream purification… (10.1093/abt/tbab007)	ORCID	41.57	45
12	Construction and next-generation sequencing analysis of a la… (10.1093/abt/tby011)	ORCID	41.09	43
13	Developability assessment at early-stage discovery to enable… (10.1093/abt/tbac029)	ORCID	40.84	42
14	Effects of arginine in therapeutic protein formulations: a d… (10.1093/abt/tbad022)	ORCID	40.58	41
15	Dual-mechanistic antibody-drug conjugate via site-specific s… (10.1093/abt/tbz009)	ORCID	40.05	39
16	The measurement and control of high-risk host cell proteins… (10.1093/abt/tbac002)	ORCID	38.60	34
17	Engineering antibody and protein therapeutics to cross the b… (10.1093/abt/tbac028)	ORCID	38.29	33
18	Preclinical and clinical development of therapeutic antibodi… (10.1093/abt/tbaa017)	License	37.96	32
19	DNA damaging agent-based antibody-drug conjugates for cancer… (10.1093/abt/tby007)	License	35.37	25
20	JSKN003, A NOVEL BIPARATOPIC ANTI-HER2 ANTIBODY-DRUG CONJUGA… (10.1093/abt/tbad014.009)	References ORCID	34.95	4
21	Challenges and solutions for the downstream purification of… (10.1093/abt/tbad028)	ORCID	34.95	24
22	A review of conjugation technologies for antibody drug conju… (10.1093/abt/tbaf010)	ORCID	34.95	24
23	Preclinical development of anti-BCMA immunotoxins targeting… (10.1093/abt/tby004)	ORCID License	34.95	4
24	The approval of sintilimab for classical Hodgkin's lymphoma:… (10.1093/abt/tbz005)	Abstract ORCID	34.95	4
25	Neutralizing antibodies against SARS-CoV-2: current understa… (10.1093/abt/tbaa028)	ORCID	34.04	22
26	Preclinical characterization of Sintilimab, a fully human an… (10.1093/abt/tby005)	ORCID	34.04	22
27	Insights into CD47/SIRPα axis-targeting tumor immunotherapy (10.1093/abt/tby006)	ORCID	34.04	22
28	Preclinical evaluation of MRG002, a novel HER2-targeting ant… (10.1093/abt/tbab017)	ORCID	33.56	21
29	Strategies to mitigate the on- and off-target toxicities of… (10.1093/abt/tbac014)	ORCID	31.97	18
30	Sagacity in antibody humanization for therapeutics, diagnost… (10.1093/abt/tbaa005)	ORCID	30.76	16
31	Tackling solid tumour therapy with small-format drug conjuga… (10.1093/abt/tbaa024)	License	30.10	15
32	Therapeutic targeting of tumor hypoxia and necrosis with ant… (10.1093/abt/tby010)	ORCID	30.10	15
33	Productivity and quality improvement for a symmetric bispeci… (10.1093/abt/tbac009)	ORCID	29.40	14
34	Reforming solid tumor treatment: the emerging potential of s… (10.1093/abt/tbae005)	ORCID	29.40	14
35	Efficient production of bispecific antibodies—optimization o… (10.1093/abt/tbad013)	ORCID	28.65	13
36	Application of an integrated computational antibody engineer… (10.1093/abt/tbab011)	References	27.85	12
37	Novel development strategies and challenges for anti-Her2 an… (10.1093/abt/tbac001)	ORCID	27.85	12
38	Development of a human glioblastoma model using humanized DR… (10.1093/abt/tbad021)	ORCID	27.85	12
39	A novel antibody targeting TIM-3 resulting in receptor inter… (10.1093/abt/tbaa022)	ORCID	26.98	11
40	AB-Amy: machine learning aided amyloidogenic risk prediction… (10.1093/abt/tbad007)	ORCID	26.98	11
41	Perspectives on the development of antibody-drug conjugates… (10.1093/abt/tbab023)	ORCID	26.03	10
42	Frontiers and Opportunities: Highlights of the 2nd Annual Co… (10.1093/abt/tby009)	ORCID	26.03	10
43	Augmenting recombinant antibody production in HEK293E cells:… (10.1093/abt/tbac003)	ORCID	25.00	9
44	Preclinical studies of BB-1701, a HER2-targeting eribulin-co… (10.1093/abt/tbae019)	License	25.00	9
45	Antibody conjugation and formulation (10.1093/abt/tbz002)	ORCID	25.00	9
46	Cross-species higher sensitivities of FcγRIIIA/FcγRIV to afu… (10.1093/abt/tbab016)	ORCID	23.86	8
47	Targeting the cancer neoantigens p53 and KRAS with TCR mimic… (10.1093/abt/tbab021)	Abstract License	23.86	2
48	A novel bispecific antibody CVL006 superior to AK112 for dua… (10.1093/abt/tbaf012)	ORCID	23.86	8
49	T-cell receptor mimic (TCRm) antibody therapeutics against i… (10.1093/abt/tbz001)	ORCID	23.86	8
50	Mini-review: antibody therapeutics targeting G protein-coupl… (10.1093/abt/tbaa023)	ORCID	22.58	7